Quick Answer
PAVmed Inc. reported Diluted EPS of $5.63 per share (loss) for fiscal year 2025.
PAVmed Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.63 | -137.8% |
| 2024 | $14.90 | +262.7% |
| 2023 | -$9.16 | +39.1% |
| 2022 | -$15.03 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.29 | -120.1% | +60.8% |
| June 30, 2025 | -$0.74 | +37.8% | -317.6% |
| March 31, 2025 | $0.34 | +113.0% | -76.4% |
| September 30, 2024 | $1.44 | +160.5% | +221.0% |
| June 30, 2024 | -$1.19 | +43.3% | +54.6% |
| March 31, 2024 | -$2.62 | +5.8% | -10.1% |
| September 30, 2023 | -$2.38 | -720.7% | -13.3% |
| June 30, 2023 | -$2.10 | -624.1% | +24.5% |
- PAVmed Inc. showed a decrease of -137.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, PAVmed Inc.’s diluted eps has grown by 62.5% (from $15.03 per share (loss) to $5.63 per share (loss)).
- The most recent figure is from PAVmed Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: